Varian Medical Systems — Q2 2018 Earnings Presentation
36 slides from Varian Medical Systems's earnings presentation, Apr 25, 2018
Slide 1: Second Quarter Fiscal Year 2018
J. Michael Bruff Senior Vice President, Investor Relations [email protected] April 25, 2018 Second Quarter Fiscal Year 2018
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Slide 3: Long-Term Strategy
Long-Term Strategy OOO
Slide 4: Global leader in radiation therapy
Eclipse ™ Treatment planning system RapidPlan ™ Knowledge - based planning software Calypso ® Real - time tracking technology Edge ™ System Full - body radiosurgery platform Halcyon ™ Image - guided IMRT treatment platform; launched kV cone beam CT imaging at ESTRO 2018 TrueBeam ® /VitalBeam ™ Trilo
Slide 5: Long-term growth and value creation strategy
Long - term growth and value creation strategy 5 Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology
Slide 6: Long-term growth strategy: Expanding addressable markets
Long - term growth and value creation strategy Expanding Addressable Markets 6 Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology Surgical oncology Diagnostic imaging Radiation oncology Precision medicine Medical oncology Generate insights Call on all onc
Slide 7: Varian to acquire Sirtex
Enables entry into a faster growing interventional oncology market Strengthening radiation medicine Investing in growth and providing financial return to shareholders • Two global leaders in radiation coming together as the leader in radiation medicine • Expands Varian’s addressable market into inte
Slide 8: Growth priorities and strategic enablers
Growth priorities and strategic enablers 8 We are here Global Leader in Radiation Therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Long - Term Growth and Value Creation Strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Marke
Slide 9: Growth priority: Strengthen our leadership in radiation therapy
Growth priority: Strengthen our leadership in radiation therapy (1) Based on company estimates and industry reports and data Enhanced quality assurance capabilities with acquisition of Mobius, a leader in radiation oncology QA software Global market leader in radiation therapy, increasing share in a
Slide 10: Growth priority: Extend global footprint
Growth priority: Extend global footprint ~55% international orders mix in Oncology in the quarter; ⁃ EMEA orders growth of 11% ⁃ APAC orders growth of 3% ⁃ Double - digits Latin American orders growth >40% of Halcyon orders in emerging markets, since May 2017 launch ⁃ >60% orders in the 2 nd quarter
Slide 11: Growth priority: Expand addressable market
Growth priority: Expand addressable market Entering interventional oncology market with acquisition of Sirtex ⁃ Leader in radioembolization within the interventional oncology market ⁃ Expected to close by late May 2018 Enhanced clinical workflow capabilities for 360 Oncology with acquisition of Evin
Slide 12: 2Q FY 2018 Business Highlights
2Q FY 2018 Business Highlights
Slide 13: Year in review
JUN First patient treated with Varian HyperArc high - definition radiotherapy Varian publishes 2017 Sustainability Report Year in review 13 AUG OCT DEC JAN FEB MARCH 2018 Varian names new CFO Varian Eclipse users generate highest scoring plans in international treatment plan competition Varian insta
Slide 14: Financial highlights
0% 5% 10% 15% 20% 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 +2 pts Y/Y Cash Flow from Operations 1 ($M) $0 $50 $100 $150 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Non - GAAP Operating Earnings (% of Revenues) Financial highlights Operating Trends* Strong performance in key financial measures • Revenues
Slide 15: Varian linac install base
Varian linac install base Install Base Trends Varian strengthened its global leadership in radiation therapy • Each geography grew respective install base in the second quarter 15 Q3FY17 Total Q1FY18 Q2FY17 Q4FY17 Q2FY18 7,691 7,954 +3%
Slide 16: Key wins
Key wins Americas EMEA APAC Sweden – Karolinska tender 8 TrueBeams UK – Glasgow Beatson & Edinburgh Western 3 TrueBeams Czech Republic – Praha MOTOL 3 TrueBeams India – Himalaya 3 Halcyon systems Mexico Instituto Mexicano del Seguro Social (IMSS) 7 Linacs – 1 Edge, 6 VitalBeams Brazil and Argentina
Slide 17: 2Q FY 2018 Financial Overview
2Q FY 2018 Financial Overview
Slide 18: Varian consolidated (GAAP) Key P&L Financial Metrics
Varian consolidated (GAAP) Key P&L Financial Metrics 18 VARIAN FISCAL 2018 $M 2Q Y/Y Gross Orders $666 0% Revenues $730 10% Product $400 10% Services $330 10% Gross Margin $318 16% % of Revenues 43.6% 208 bps SG&A $165 25% % of Revenues 22.6% 271 bps R&D $59 10% % of Revenues 8.1% 3 bps Operating Ea
Slide 19: Varian consolidated (non-GAAP) Key P&L Financial Metrics
VARIAN FISCAL 2018 $M 2Q Y/Y Gross Orders $666 0% Revenues $730 10% Product $400 10% Services $330 10% Gross Margin $320 16% % of Revenues 43.8% 209 bps SG&A $132 12% % of Revenues 18.1% 38 bps R&D $59 10% % of Revenues 8.1% 3 bps Operating Earnings $129 22% % of Revenues 17.6% 168 bps EPS ($) $1.15
Slide 20: Varian consolidated Key Balance Sheet and Cash Flow Metrics
Varian consolidated Key Balance Sheet and Cash Flow Metrics • Cash Flow from Operations more than doubled, driven by operating income performance and working capital efficiencies Trailing twelve - month cash flow from operations of $529 million Oncology DSO down from 118 to 103 days • Continuing to
Slide 21: Oncology operating segment Key Financial Metrics
Oncology operating segment Key Financial Metrics • Orders growth of 5% (+1% cc), with growth in all regions Oncology orders mix: North America ~45%, International ~55% 19 new orders for Halcyon in the quarter • Product revenues growth of 11% driven by robust linac system sales, services, and softwar
Slide 22: Oncology gross orders by geography
22 Oncology gross orders by geography AMERICAS 2% 2Q Y/Y (+2% cc) 1% 2Q TTM 1 (+1% cc) APAC 3% 2Q Y/Y (+1% cc) 2% 2Q TTM (+2% cc) EMEA 11% 2Q Y/Y (+0% cc) 15% 2Q TTM (+11% cc) (1) In North America, trailing twelve - month orders growth of 2% in dollars and constant currency
Slide 23: Particle Therapy operating segment Key Financial Metrics
Particle Therapy operating segment Key Financial Metrics • No new orders for ProBeam systems in the quarter; 6 orders in the trailing twelve months; pipeline remains strong • 7 operational sites with 25 rooms in 5 countries; 16 more sites in progress across the world • Revenues, margins and related
Slide 24: ProBeam proton therapy system sites
ProBeam proton therapy system sites Operational Centers Centers Under Development 24 Treatment rooms ProBeam Sites Operational rooms Operational Sites 70 25 7 23
Slide 25: FY 2018 Guidance
FY 2018 Guidance
Slide 26: Updated Fiscal Year 2018 Guidance
Varian consolidated Updated Fiscal Year 2018 Guidance Updating full fiscal year 2018 guidance after considering the following: • First, continued projected market growth • Second, our products and solutions continue to resonate in the market driving share gains • Third, recent tailwinds in the curre
Slide 27: 2Q FY 2018 Financial Overview
2Q FY 2018 Financial Overview
Slide 28: Non-GAAP disclosure
Non - GAAP disclosure 28 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted
Slide 29: GAAP to non-GAAP reconciliation
GAAP to non - GAAP reconciliation 29 (1) Includes $1.2 million, $1.2 million, $1.3 million, $1.2 million, and $1.5 million, respectively in cost of revenues for the p eri ods presented. (2) In the second quarter of 2018, there was primarily $16.4 million for the hedging loss related to the Australia
Slide 30: Total revenues by sales classification
Total revenues by sales classification 30 CC – Constant currency $M 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Product revenues $364.9 $326.2 $402.8 $365.6 $400.4 Y/Y 10% Service revenues $298.3 $306.6 $319.0 $312.9 $329.5 Y/Y 10% Total revenues $663.2 $632.8 $721.8 $678.5 $729.9 Y/Y 10% Y/Y – CC 6% Pr
Slide 31: Total revenues by product type
Total revenues by product type 31 CC – Constant currency
Slide 32: Total revenues by region
Total revenues by region 32 $M 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Americas revenues $341.6 $336.3 $368.6 $356.7 $340.2 Y/Y 0% Y/Y – CC - 1% EMEA revenues $185.3 $169.5 $220.4 $193.0 $253.8 Y/Y 37% Y/Y – CC 23% APAC revenues $136.3 $127.0 $132.8 $128.8 $135.9 Y/Y 0% Y/Y – CC - 3% Total revenues
Slide 33: Total Oncology revenues by sales classification
Total Oncology revenues by sales classification 33 $M 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Product revenues $334.8 $259.7 $353.7 $338.3 $370.3 Y/Y 11% Y/Y – CC 6% Service revenues $297.1 $304.7 $315.6 $311.1 $327.7 Y/Y 10% Y/Y – CC 6% Total revenues $631.9 $564.4 $669.3 $649.4 $698.0 Y/Y 10% Y/Y
Slide 34: Total Oncology revenues by region
Total Oncology revenues by region 34 $M 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Americas revenues $332.0 $286.9 $347.1 $337.4 $321.2 Y/Y - 3% Y/Y – CC - 3% EMEA revenues $167.5 $157.6 $196.9 $183.5 $241.2 Y/Y 44% Y/Y – CC 29% APAC revenues $132.4 $119.9 $125.3 $128.5 $135.6 Y/Y 2% Y/Y – CC 0% Total
Slide 35: Total Particle Therapy revenues by sales classification
Total Particle Therapy revenues by sales classification 35 $M 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Product revenues $30.1 $66.5 $49.1 $27.3 $30.1 Y/Y 0% Service revenues $1.2 $1.9 $3.4 $1.8 $1.8 Y/Y 61% Total revenues $31.3 $68.4 $52.5 $29.1 $31.9 Y/Y 2% VPT revenues as a percentage of total reve
Slide 36: Oncology gross orders by region
Oncology gross orders by region 36 $M 2Q FY17 3Q FY17 4Q FY17 1Q FY18 2Q FY18 Americas orders $335.2 $331.9 $479.0 $299.5 $341.4 Y/Y 2% Y/Y – CC 2% EMEA orders $180.3 $204.5 $315.4 $190.4 $199.3 Y/Y 11% Y/Y – CC 0% APAC orders $119.5 $151.3 $153.0 $130.0 $123.4 Y/Y 3% Y/Y – CC 1% Total orders $635.0
Varian Medical Systems — Q2 2018 Earnings Presentation on 6ix